Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors
Authors:
- 1 May 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of Affective Disorders
- Vol. 86 (1) , 99-104
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The Effectiveness of Olanzapine, Risperidone, Quetiapine, and Ziprasidone as Augmentation Agents in Treatment-Resistant Major Depressive DisorderThe Journal of Clinical Psychiatry, 2004
- Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitorsDepression and Anxiety, 2004
- Ziprasidone Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) for SSRI-Resistant Major Depressive DisorderThe Journal of Clinical Psychiatry, 2004
- A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar ManiaAmerican Journal of Psychiatry, 2003
- The Epidemiology of Major Depressive DisorderJAMA, 2003
- Residual Symptoms in DepressionThe Journal of Clinical Psychiatry, 2003
- Aripiprazole: profile on efficacy and safetyExpert Opinion on Pharmacotherapy, 2002
- An Open Pilot Study Combining Risperidone and a Selective Serotonin Reuptake Inhibitor as Initial Antidepressant TherapyThe Journal of Clinical Psychiatry, 2002
- Toward a dimensional and psychometrically-informed approach to conceptualizing psychopathologyBehaviour Research and Therapy, 2002
- Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United StatesArchives of General Psychiatry, 1994